Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT00218868 Completed - Clinical trials for Carcinoma, Basal Cell

Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunwald-giemsa Stained Tissue Smear

Start date: January 2000
Phase:
Study type: Observational

The purpose of this study is to compare and evaluate the diagnostic performance of scrape cytology using two different cytological staining techniques, and to evaluate additional touch imprint cytology with that of histopathology of superficial basal cell carcinoma and actinic keratosis.

NCT ID: NCT00218829 Completed - Clinical trials for Carcinoma, Basal Cell

DMSO-PDT of BCC - A 6 Year Follow up

Start date: September 1997
Phase: N/A
Study type: Observational

The purpose of this study is to registrate long time clinical and histological treatment response of basal cell carcinoma (BCC) lesions treated with one or two procedures of dimethylsulfoxide supported 5-aminolaevulinic acid photodynamic therapy (DMSO-PDT).

NCT ID: NCT00217633 Completed - Clinical trials for Cervical Adenocarcinoma

Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well pelvic exenteration works in treating patients with recurrent cervical cancer. Pelvic exenteration may be effective in treating recurrent cervical cancer.

NCT ID: NCT00216645 Completed - Ovarian Neoplasms Clinical Trials

Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effectiveness and safety of pegylated liposomal doxorubicin hydrochloride injection in Japanese patients with Mullerian carcinoma. This clinical study is a multi-center, non-randomized, open-label study in Japanese patients with Mullerian carcinoma (including epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) with a prior history of platinum-based chemotherapy. Eighty patients will be administered intravenously at least two cycles of 50 mg/m2 of pegylated liposomal doxorubicin hydrochloride every 4 weeks to investigate the effectiveness and safety of the treatment.

NCT ID: NCT00216372 Completed - Carcinoma Clinical Trials

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Start date: September 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether lanreotide 30mg microparticles are effective in the relief of clinical symptoms due to small bowel obstruction in inoperable patients with peritoneal carcinomatosis.

NCT ID: NCT00215202 Completed - Clinical trials for Nonresectable Adrenocortical Carcinoma

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Start date: August 2004
Phase: Phase 2
Study type: Interventional

The use of Iressa will result in a greater than 20% response rate in patients with nonresectable adrenocortical cancer who have previously been treated with one other form of systemic therapy (either Mitotane or chemotherapy).

NCT ID: NCT00214058 Completed - Clinical trials for Primary Peritoneal Carcinoma

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

Start date: August 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer

NCT ID: NCT00212108 Completed - Clinical trials for Nasopharyngeal Carcinoma

A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839

Start date: November 2003
Phase: Phase 1/Phase 2
Study type: Interventional

EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action between COX-2 and EGFR inhibitors. Study hypothesis: Celecoxib and gefitinib can reduce angiogenesis and induce anti-tumorigenicity in patients with nasopharngeal cancer.

NCT ID: NCT00207116 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Start date: September 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer

NCT ID: NCT00206219 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Start date: November 2003
Phase: Phase 3
Study type: Interventional

This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.